ACX10061 News
Most Popular ACX10061 Story
Addex smoking cessation drug misses endpoint
ADX10061--Addex Pharmaceuticals' smoking cessation drug--did not meet the primary efficacy endpoint in a Phase IIa. The primary endpoint was to assess whether the drug increased the number of... Read more...
Latest Headlines
- October 1, 2007
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
